Smoldering myeloma associated with zonisamide treatment.
A 39-year-old man was found to have hyperproteinemia after being treated with zonisamide for 10 years. Laboratory examination revealed a serum M-protein which consisted of IgG (lambda) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma. Considering his age, zonisamide was suspected to play an etiologic role in the occurrence of smoldering myeloma. Zonisamide was changed to sodium valproate. Subsequently the M-protein did not increase over 13 months. When zonisamide is used, the monitoring of serum levels of M-protein and patterns of gammaglobulin is warranted.
Asai
Satomi
S
Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Kanagawa.
Miyachi
Hayato
H
Kobayashi
Hiroyuki
H
Hotta
Tomomitsu
T
Ando
Yasuhiko
Y
D000328:Adult; D000361:Agammaglobulinemia / Q000097:blood / Q000139:chemically induced*; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D004829:Epilepsy, Generalized / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007146:Immunoglobulin lambda-Chains / Q000097:blood*; D002538:Intracranial Arteriovenous Malformations / Q000150:complications; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009101:Multiple Myeloma / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D009194:Myeloma Proteins / Q000032:analysis*; D013345:Subarachnoid Hemorrhage / Q000150:complications; D014635:Valproic Acid / Q000627:therapeutic use; D000078305:Zonisamide
D000927:Anticonvulsants; D007146:Immunoglobulin lambda-Chains; D007555:Isoxazoles; D009194:Myeloma Proteins; D000078305:Zonisamide; D014635:Valproic Acid